Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
NCT04104997 is registered in ClinicalTrials.gov with GL Pharm Tech Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
- Lead sponsor
- GL Pharm Tech Corporation
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 26, 2019
- Completion date
- July 17, 2020
- Enrollment
- 39 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.